Apricoxib (CAS 197904-84-0)
QUICK LINKS
Apricoxib is a compound examined in various research applications, mainly regarding its role as a COX-2 inhibitor. Studies often focus on the compound′s impact on the synthesis of prostaglandins, which are lipid compounds involved in the regulation of inflammation and pain signaling pathways. Researchers investigate the effects of Apricoxib on cellular signaling cascades and gene expression related to the inflammatory response. In biochemical assays, Apricoxib is used to delineate the selectivity and potency of COX-2 inhibition and to understand the structural requirements for binding to the enzyme. Additionally, the compound′s influence on the arachidonic acid metabolic pathway is a key area of interest, as this pathway produces various bioactive molecules.
Apricoxib (CAS 197904-84-0) References
- Predictive population pharmacokinetic/pharmacodynamic model for a novel COX-2 inhibitor. | Rohatagi, S., et al. 2007. J Clin Pharmacol. 47: 358-70. PMID: 17322148
- Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects. | Ushiyama, S., et al. 2008. Eur J Pharmacol. 578: 76-86. PMID: 17920584
- Apricoxib, a COX-2 inhibitor for the potential treatment of pain and cancer. | Rao, PN. and Grover, RK. 2009. IDrugs. 12: 711-22. PMID: 19844858
- Efficient synthesis of apricoxib, CS-706, a selective cyclooxygenase-2 inhibitor, and evaluation of inhibition of prostaglandin E2 production in inflammatory breast cancer cells. | Mandal, PK., et al. 2011. Bioorg Med Chem Lett. 21: 6071-3. PMID: 21903394
- First-line treatment of metastatic pancreatic cancer. | Tokh, M., et al. 2012. JOP. 13: 159-62. PMID: 22406590
- Epithelial-mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib. | Kirane, A., et al. 2012. Carcinogenesis. 33: 1639-46. PMID: 22678114
- Apricoxib upregulates 15-PGDH and PGT in tobacco-related epithelial malignancies. | St John, MA., et al. 2012. Br J Cancer. 107: 707-12. PMID: 22828609
- Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer. | Kirane, A., et al. 2012. Clin Cancer Res. 18: 5031-42. PMID: 22829202
- Brief overview of selected approaches in targeting pancreatic adenocarcinoma. | Samore, WR. and Gondi, CS. 2014. Expert Opin Investig Drugs. 23: 793-807. PMID: 24673265
- Combination Treatment with Apricoxib and IL-27 Enhances Inhibition of Epithelial-Mesenchymal Transition in Human Lung Cancer Cells through a STAT1 Dominant Pathway. | Lee, MH., et al. 2014. J Cancer Sci Ther. 6: 468-477. PMID: 26523208
- Cyclooxygenase-2 inhibitors in lung cancer treatment: Bench to bed. | Liu, R., et al. 2015. Eur J Pharmacol. 769: 127-33. PMID: 26548623
- Efficacy and safety of COX-2 inhibitors for advanced non-small-cell lung cancer with chemotherapy: a meta-analysis. | Dai, P., et al. 2018. Onco Targets Ther. 11: 721-730. PMID: 29440919
- Identification of potential candidate genes for lip and oral cavity cancer using network analysis. | Mathavan, S., et al. 2021. Genomics Inform. 19: e4. PMID: 33840168
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Apricoxib, 10 mg | sc-481189 | 10 mg | $401.00 |